Reneo Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 13.6 million compared to USD 10.61 million a year ago. Basic loss per share from continuing operations was USD 0.56 compared to USD 0.43 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 USD | -0.53% | +16.67% | +18.12% |
May. 16 | Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing | MT |
May. 13 | Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.12% | 63.17M | |
+44.48% | 55.07B | |
+43.57% | 40.22B | |
-0.86% | 41.79B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- RPHM Stock
- News Reneo Pharmaceuticals, Inc.
- Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022